BioCube, Inc.
BICB · OTC
10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.34 | -0.00 | 5.38 |
| FCF Yield | 1.99% | -0.35% | -0.06% | -0.13% |
| EV / EBITDA | -64.92 | -110.72 | -58.32 | 13.32 |
| Quality | ||||
| ROIC | -53.97% | -44.06% | -47.79% | 0.00% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | -1.31 | 0.38 | 0.01 | 2.71 |
| Growth | ||||
| Revenue 3-Year CAGR | 451,502.52% | 386,704.93% | 309,371.87% | -100.00% |
| Free Cash Flow Growth | 370.85% | -633.53% | 64.21% | 78.95% |
| Safety | ||||
| Net Debt / EBITDA | 0.57 | -0.58 | -0.13 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 4.66 | 43.33 | 56.71 | 0.00 |